FGP
HALO icon

Freestone Grove Partners’s Halozyme HALO Stock Holding History

Freestone Grove Partners’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
20,719
+5,183
+33% +$365K 0.01% 425
2025
Q4 		$1.05M Buy
+15,536
New +$1.05M 0.01% 462
2025
Q3 		– Sell
-11,867
Closed -$617K – 795
2025
Q2 		$617K Buy
+11,867
New +$675K ﹤0.01% 496
2025
Q1 		– Sell
-6,839
Closed -$327K – 673
2024
Q4 		$327K Buy
+6,839
New +$351K ﹤0.01% 452

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's HALO Position: Q1 2026 in Review

Freestone Grove Partners increased its Halozyme (HALO) stake by 33% in Q1 2026, buying an estimated $365K and bringing the position to 20,719 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #425.

Freestone Grove Partners first reported a position in HALO in Q4 2024 and has held it in 4 quarters since. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Freestone Grove Partners held 20,719 shares of Halozyme worth $1.34M as of Q1 2026.
  • Freestone Grove Partners bought 5,183 Halozyme shares in Q1 2026, an estimated $365K.
  • Halozyme made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #425 holding.
  • Freestone Grove Partners first reported a position in Halozyme in Q4 2024 and has held it in 4 quarters since.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.